New hope for advanced cancer: ALK-N001 enters human trials
NCT ID NCT07509684
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called ALK-N001 in 190 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every 2 or 3 weeks. Researchers will check if it shrinks tumors, how safe it is, and how the body processes it. The goal is to find a new option for people with few choices left.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ALK-N001 (also called QHL-1618), given as an intravenous infusion over 2 hours every 2 or 3 weeks
- What this could lead to
- If successful, this could provide a new treatment option for people with advanced solid tumors who have run out of standard therapies.
- What could go wrong
- This is an early-phase trial (Phase Ib/II) with a small number of participants, so the drug may not prove effective or safe enough for wider use. Side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a pill outsmart Tumors' defenses?
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?